Search

Displaying results 4131 - 4140 of 5898 in total
  1. Drug

    EHT899

    go.drugbank.com/drugs/DB05108
    Experimental

    EHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune response elicited by the HBV infection. … It also apparently enhances a secondary immune response to clear the viral infection, resulting in reduction in liver damage and decrease in viral load.

  2. Drug

    Tecadenoson

    go.drugbank.com/drugs/DB04954
    Investigational

    Tecadenoson is a novel selective A1 adenosine receptor agonist that is currently being evaluated for the conversion of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm.

  3. Drug

    SPC2968

    go.drugbank.com/drugs/DB06351
    Investigational

    It was under investigation in clinical trial NCT02564614 (A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult

  4. Drug

    Tipifarnib

    go.drugbank.com/drugs/DB04960
    Investigational

    It belongs to the family of drugs called farnesyltransferase inhibitors. It is also called Zarnestra. In June 2005, the FDA issued a Not Approvable Letter for Zarnestra.

  5. Drug

    COVID-19 convalescent plasma

    go.drugbank.com/drugs/DB15692
    Investigational

    COVID-19 convalescent plasma is plasma collected from patients who have acquired and subsequently recovered from COVID-19 and which contains antibodies against the causative agent SARS-CoV-2. … [L14333] Although there are no formal clinical trial results for the safety or efficacy of COVID-19 convalescent plasma, early results from 5000 patients under the FDA expanded access program suggest

  6. Drug

    SLV319

    go.drugbank.com/drugs/DB05077
    Experimental

    SLV319 belongs to a novel class of agents called CB1 antagonists, which work by blocking the cannabinoid type 1 (CB1) receptor.

  7. Drug

    CYP-001

    go.drugbank.com/drugs/DB15739
    Investigational

    These cells are used to treat chronic allergic airway disease and fibrosis, among other pathologies. … These cells are then able to differentiate into bone, cartilage, and adipose tissue. The MCA-derived MSCs can be obtained from induced pluripotent stem cells (iPSCs) and then expanded in media.

  8. Drug

    TRX1

    go.drugbank.com/drugs/DB05863
    Experimental

    TRX1 is a humanized antibody that binds to the CD4 receptor found on a subset of T cells.

  9. Drug

    Vamotinib

    go.drugbank.com/drugs/DB15396
    Investigational

    Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene). … Vamotinib (PF-114) is under investigation in clinical trial NCT02885766 (Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With

  10. Drug

    AVAC

    go.drugbank.com/drugs/DB05441
    Experimental

    It has been tested in uses related to asthma and in treating eczema and atopic dermatitis. … [Mycobacterium vaccae] is a non-pathogenic, saprophytic bacteria whose antigens can be used to induce peripheral immune activation through the activity of regulatory T-cells that surpress inappropriate